Fubon NYSE Factset Global Genomics and Immuno Biopharma ETF

Fubon NYSE Factset Global Genomics and Immuno Biopharma ETF is offered by Fubon, a leading player in the field of passive investments.

The total expense ratio of Fubon NYSE Factset Global Genomics and Immuno Biopharma ETF is 1.05%, which means that investors pay 105 TWD per 10,000 TWD in investment capital annually.

The ETF is listed in TWD.

European investors may incur additional costs for currency exchange and transaction fees.

No, Fubon NYSE Factset Global Genomics and Immuno Biopharma ETF does not comply with the EU UCITS investor protection directives.

The P/E ratio of Fubon NYSE Factset Global Genomics and Immuno Biopharma ETF is 16.1.

Fubon NYSE Factset Global Genomics and Immuno Biopharma ETF tracks the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index.

Fubon NYSE Factset Global Genomics and Immuno Biopharma ETF is domiciled in TW.

The fund was launched on 10/4/2021.

The Fubon NYSE Factset Global Genomics and Immuno Biopharma ETF mainly invests in Topic companies.

The NAV of Fubon NYSE Factset Global Genomics and Immuno Biopharma ETF amounts to 9.67 M TWD.

The price-to-book ratio is 2.935.

Investments can be made through brokers or financial institutions that provide access to trading ETFs.

The ETF is traded on the stock exchange, similar to stocks.

Yes, the ETF can be held in a regular securities account.

The ETF is suitable for both short-term and long-term investment strategies, depending on the investor's goals.

The ETF is valued on a daily stock exchange basis.

Information on dividends should be requested from the provider's website or your broker.

The risks include market fluctuations, currency risks, and the risk associated with smaller companies.

The ETF is obligated to report regularly and transparently on its investments.

The performance can be viewed on Eulerpool or directly on the provider's website.

Further information can be found on the official website of the provider.